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Abstract
Background: Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of treatment with some
atypical antipsychotic drugs in children and youth. Because drug-associated DKA is rare, large automated health
outcomes databases may be a valuable data source for conducting pharmacoepidemiologic studies of DKA
associated with exposure to individual antipsychotic drugs. However, no validated computer case definition of DKA
exists. We sought to assess the positive predictive value (PPV) of a computer case definition to detect incident
cases of DKA, using automated records of Tennessee Medicaid as the data source and medical record confirmation
as a “gold standard.”
Methods: The computer case definition of DKA was developed from a retrospective cohort study of antipsychotic-
related type 2 diabetes mellitus (1996-2007) in Tennessee Medicaid enrollees, aged 6-24 years. Thirty potential
cases with any DKA diagnosis (ICD-9 250.1, ICD-10 E1x.1) were identified from inpatient encounter claims. Medical
records were reviewed to determine if they met the clinical definition of DKA.
Results: Of 30 potential cases, 27 (90%) were successfully abstracted and adjudicated. Of these, 24 cases were
confirmed by medical record review (PPV 88.9%, 95% CI 71.9 to 96.1%). Three non-confirmed cases presented
acutely with severe hyperglycemia, but had no evidence of acidosis.
Conclusions: Diabetic ketoacidosis in children and youth can be identified in a computerized Medicaid database
using our case definition, which could be useful for automated database studies in which drug-associated DKA is
the outcome of interest.
Background
Diabetic ketoacidosis is a severe and potentially life-
threatening complication of both type 1 and type 2 dia-
betes mellitus. While poor adherence to diabetes treat-
ment is the major precipitant of diabetic ketoacidosis
(DKA) [1], exposure to atypical antipsychotic drugs has
also been linked with DKA development [2,3]. DKA
occurrence among individuals exposed to atypical anti-
p s y c h o t i cd r u g si s1 0 - t i m e st h a to ft h eg e n e r a l
population [4]. The risk of atypical antipsychotic
drug-associated DKA may be even higher in children
and youth, who appear to be more susceptible to treat-
ment-emergent weight gain and hyperglycemia than
adults [5]. Even so, drug-associated DKA occurs infre-
quently. Clinical trials and prospective cohort studies
are therefore unlikely to have sufficient power for
detecting inter-drug differences in DKA occurrence.
Large automated medical encounter databases are
therefore a valuable data source for observational studies
of DKA risk related to atypical antipsychotic drug use,
particularly for relatively under-studied patient sub-
groups including children and youth [6]. Such databases
* Correspondence: william.b.bobo@vanderbilt.edu
1Department of Psychiatry; Vanderbilt University School of Medicine;
Nashville, Tennessee USA
Full list of author information is available at the end of the article
Bobo et al. BMC Medical Research Methodology 2011, 11:157
http://www.biomedcentral.com/1471-2288/11/157
© 2011 Bobo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.include computerized records of prescriptions written by
clinicians, filled by patients or caregivers or adminis-
tered in institutions, which provide objective, detailed,
reliable, and relatively low-cost measures of drug expo-
sure [6]. Database records of medical encounters may
also allow identification of newly diagnosed cases of
DKA; however, these records are also subject to misclas-
sification [6,7]. To conduct studies of DKA associated
with atypical antipsychotic drug exposure with auto-
mated databases, a reliable definition of incident cases is
essential. However, we are unaware of a validated com-
puter case definition of DKA.
We therefore tested a computer case definition of
incident DKA designed for use in automated databases
and report its validation here using a sample from a ret-
rospective cohort study of antipsychotic drug-associated
type 2 diabetes risk in a Medicaid population of children
and youth.
Methods
Sources of Data
The automated database case definition was based upon
information from an in-progress retrospective cohort
study of antipsychotics on the risk of type 2 diabetes in
children and youth [8]. The study utilizes computerized
files from the Tennessee Medicaid Program, including
an enrollment file and files recording prescriptions filled
at a pharmacy, hospital admissions, outpatient visits,
and long-term care residence. Medicaid files are linked
with computerized death certificates and with the State
Hospital Discharge File, an “all-payers” database of hos-
pital discharges and emergency room visits, which pro-
vides information occasionally missing from Medicaid
files. These files permitted identification of study popu-
lations, tracking of study medication use, classification
of subjects according to baseline diabetes risk factors,
and ascertainment of potential diabetes and DKA cases.
Study Cohort
The underlying cohort consisted of children and youth
(aged 6-24 years) enrolled in Medicaid from 1/1/1996
through 12/31/2007. Cohort membership required that
during the past year there was adequate enrollment and
health care utilization to assure availability of data
needed for study variables; no evidence of life-threaten-
ing illness or institutional residence; no diagnosis of
schizophrenia, related psychotic disorder, or other con-
dition for which antipsychotics are the only recom-
mended treatment; no evidence of type 1 or type 2
diabetes; and no evidence of pregnancy or polycystic
ovarian syndrome (to reduce endpoint misclassification).
Cohort members could not have been in the hospital in
the past 30 days because Medicaid files do not include
in-hospital medications.
The cohort consisted of recent initiators of antipsy-
chotics or control medications (mood stabilizers,
ADHD drugs, antidepressants, benzodiazepines).
Recent initiators filled a qualifying prescription for a
study drug, had no prescription filled more than 90
days prior to the qualifying prescription, and had at ≥
365 prior consecutive days with no filled prescription.
Follow-up began on the day following the prescription
fill and ended with the end of the study, the 25th
birthday, loss of enrollment, death, failure to meet
study inclusion/exclusion criteria, or 365 days follow-
ing the last day of current use of a study drug, which-
ever came first.
Computer Case Definition for DKA
Potential cases of DKA were identified, which served as
the study validation sample. Potential cases were identi-
fied from inpatient medical care encounter claims with
any diagnosis consistent with DKA (ICD-9 250.1, ICD-
10 E1x.1). Outpatient encounter claims were excluded.
The index date for DKA events was set as the date of
hospital admission, unless there was also a claim for
emergency room care for any diabetes diagnosis (ICD-9
250x) on the day prior to admission. In this case, the
index date was reset to the date of the emergency
department visit. From the initial cohort (N = 203,462),
a total of 30 potential DKA cases were identified that
met these criteria, which served as the study validation
sample.
For potential cases, trained study nurses, masked to
drug exposure status, abstracted records of pertinent
medical care, redacted to conceal patient identifying
information. Study nurses confirmed the demographic
information from abstracted records, and recorded any
pertinent signs, symptoms, laboratory study results,
treatment interventions and clinical diagnoses made
during hospitalization.
Abstracted records were independently adjudicated
by two investigators, masked to case exposure status.
Confirmed cases were those in which both adjudica-
tors agreed that the case met pre-specified diagnostic
criteria based on current guidelines [9]. This required
a random blood glucose > 250 mg/dL and any of the
following: a) blood pH < 7.25 (venous) or 7.30 (arterial
or capillary); b) blood bicarbonate < 15 mmol/L; c)
discharge diagnosis of DKA (ICD-9 250.1, ICD-10
E1x.1). Cases with no laboratory evidence of acidosis
were not considered confirmed cases, even if a dis-
charge diagnosis of DKA was given. Study procedures
allowed for the resolution of disagreements between
adjudicators by a third reviewer; however, no such dis-
agreement occurred. The study was approved by the
Institutional Review Board at Vanderbilt University
Medical Center.
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The positive predictive value (PPV) of the DKA case
definition was calculated with 95% confidence intervals
(CI) for binomial proportions using Wilson’sf o r m u l a .
Case confirmation from medical record review served as
the gold standard. Analyses were conducted using
STATA statistical software, version 11.0 (STATA Cor-
poration; College Station, Texas, USA).
Results
Our validation sample was relatively young in age, pre-
dominantly Caucasian, and urban-dwelling (Table 1). As
expected, the prevalence of mental health diagnoses was
high, particularly attention deficit-hyperactivity disorder
and mood disorders.
Of the 30 potential cases identified from the main
cohort, 27 (90%) were abstracted and adjudicated.
Reasons for incomplete abstraction included the inability
to locate the medical record (n = 2) and refusal of the
health care facility to participate (n = 1). The full valida-
tion sample and adjudicated cases were similar with
respect to clinical and demographic characteristics.
Of the 27 adjudicated cases, 24 were confirmed cases
of incident DKA (PPV 88.9%, 95% CI 71.9 to 96.1%)
(Table 2). The three non-confirmed cases presented
acutely with severe hyperglycemia and ketosis, but had
no evidence of acidosis.
We performed separate PPV calculations for persons
in the validation sample who were exposed to antipsy-
chotic drugs, and for those who were exposed to control
medications (Table 2). Five of six recent antipsychotic
drug initiator cases were confirmed cases of incident
DKA (PPV 83.3%, 95% CI 43.6 to 97.0%). Nineteen of
21 cases from recent initiators of control medications
were confirmed incident DKA cases (PPV 90.0%, 95%
CI 71.1 to 97.3%).
Table 1 Demographic and clinical characteristics of
validation study sample
Characteristic
a All cases Adjudicated
N3 0 2 7
Age, years, median (IQR) 11 (7-14) 11 (8-15)
Gender, no. (%) female 14 (46.7) 13 (48.1)
Race, no. (%)
Caucasian 21 (70.0) 19 (70.4)
African-American 6 (20.0) 6 (22.2)
Other 3 (10.0) 2 (7.4)
Urban dwelling, no. (%) 19 (63.3) 17 (63.0)
General medical diagnoses, no. (%)
Any 15 (50.0) 14 (51.9)
Cardiovascular 1 (3.3) 1 (3.7)
Endocrine (non-diabetic, non-DKA) 0 0
Injury 5 (16.7) 5 (18.5)
Rheumatologic 2 (6.7) 1 (3.7)
Pregnancy 1 (3.3) 1 (3.7)
Psychiatric diagnoses, no. (%)
Mood disorder 9 (30.0) 8 (29.6)
Anxiety disorder 3 (10.0) 3 (11.1)
Attention deficit-hyperactivity disorder 16 (53.3) 15 (55.6)
Externalizing/impulse control disorders 6 (20.0) 5 (18.5)
Acute stress/adjustment disorders 5 (16.7) 3 (11.1)
Outpatient visits, median no. (IQR)
b 3 (1-10) 3 (1-10)
Medications, psychotropic, no. (%)
Antipsychotic drug 6 (20.0) 6 (22.2)
Antidepressant, SSRI or SNRI 9 (30.0) 9 (33.3)
Antidepressant, tricyclic 3 (10.0) 3 (11.1)
Antidepressant, other 1 (3.3) 1 (3.7)
ADHD (stimulants, atomoxetine) 22 (73.3) 19 (70.4)
Benzodiazepine 4 (13.3) 4 (14.8)
Mood stabilizer (VPA, CBMZ, LAM) 2 (6.7) 2 (7.4)
a Corresponds with the value at the beginning of follow-up (t0) in the study
cohort, unless otherwise specified.
b Corresponds with the value during the year prior to the beginning of
follow-up in the study cohort (e.g., the time interval [t0-365 days, t0]).
Key: ADHD = attention deficit-hyperactivity disorder, CBMZ = carbamazepine,
LAM = lamotrigine, SNRI = serotonin-norepinephrine re-uptake inhibitor
(venlafaxine, duloxetine), SSRI = selective serotonin re-uptake inhibitor
(fluoxetine, paroxetine, sertraline, citalopram, fluvoxamine, escitalopram), VPA
= valproic acid.
Table 2 Positive predictive value (PPV) of computer case
definition for diabetic ketoacidosis
PPV (%)
a
95% Confidence
Interval
a
Overall 88.9 71.9 to 96.1
Stratified analyses
By psychotropic drug
exposure
b
Antipsychotic drug 83.3 43.6 to 97.0
Other psychotropic
drugs
90.0 71.1 to 97.3
By age strata
Upper (ages 11-24 years) 100.0 81.6 to 100.0
Lower (age ≤ 10 years) 70.0 39.7 to 89.2
By gender
Male 100.0 78.5 to 100.0
Female 76.9 49.7 to 91.8
By ADHD diagnosis
Yes 80.0 54.8 to 93.0
No 100.0 75.8 to 100.0
a The positive predictive value (PPV) of the DKA case definition was calculated
with 95% confidence intervals (CI) for binomial proportions using Wilson’s
formula.
b The cohort consisted of recent initiators of antipsychotics or control
medications (mood stabilizers, ADHD drugs, antidepressants, benzodiazepines)
who filled a qualifying prescription for a study drug, had no fill more than 90
days prior to the qualifying prescription, and had at ≥ 365 prior consecutive
days with no filled prescription.
c The underlying cohort consisted of children and youth (aged 6-24 years).
Key: ADHD = attention deficit-hyperactivity disorder
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and presence of an attention deficit-hyperactivity disor-
der (ADHD) diagnosis were conducted (Table 2). All
seventeen cases from the upper age stratum (ages 11-24
years) were confirmed incident DKA cases, while 7 of
10 cases from the lower age stratum (ages 10 and
below) were so confirmed. Incident DKA was confirmed
for all 14 cases among males and for 10 of 13 cases
among females; and for 12 of 15 cases among indivi-
duals with a diagnosis of ADHD and for all 12 cases
among those with no ADHD diagnosis.
Discussion
This study demonstrates that incident DKA cases may
be identified with greater than 88% PPV using a compu-
ter case definition based on inpatient medical care
encounter claims with a diagnosis code consistent with
DKA. While uncommon, the risk of antipsychotic drug-
associated DKA is important to quantify because it is
life-threatening, and because DKA may be the first man-
ifestation of any metabolic disturbance after antipsycho-
tic drug initiation [10,11]. The risk of treatment-
emergent metabolic derangements, including DKA,
appears to vary according to specific agent [2,11]. How-
ever, five cases of DKA have been linked with aripipra-
zole [12-16], considered to be among the least
metabolically-liable atypical antipsychotics [11].
Our case definition included only inpatient claims, a
decision that was based on the high likelihood that a
majority of DKA cases would require inpatient or emer-
gency medical care. We did not require primary diag-
noses of DKA because the clinical criteria for DKA
diagnosis are well-established. Therefore, we did not
assume that diagnostic reliability was higher for primary
DKA diagnoses than that of secondary diagnoses.
To our knowledge, this is the first attempt to validate
a computer case definition for DKA intended for use in
pharmacoepidemiological studies of DKA as a study
endpoint using automated databases. Automated data-
bases may be the only efficient means of quantifying
DKA risk associated with specific drug exposures, given
how infrequently it occurs. On the other hand, there are
several challenges to conducting health outcomes stu-
dies using automated databases. The potential for mis-
classification bias is among the most serious of these
[6]. Most automated databases, including the one used
in our study, are made up of medical encounter and
other service utilization data are collected for purposes
other than research, and the quality of the collected
data can vary substantially [7]. Thus, computerized med-
ical encounter records are subject to misclassification
due to coding errors or other problems [6,7]. Endpoint
misclassification is a particular concern for database stu-
dies of medical conditionst h a ta r en o tr e l i a b l y
diagnosed or treated [7]. However, the potential for end-
point misclassification also exists for database studies in
which the endpoint of interest is DKA, a condition that
may reliably come to medical attention due to its acuity
and severity. Misclassification errors can introduce bias
that cannot be overcome using data analytic or other
techniques [6,7]. Therefore, in addition to improving the
efficiency of database studies, a validated computer-
based DKA endpoint definition is needed in order to
reduce the potential for misclassification bias and
improve the validity of study findings.
Our DKA computer case definition was developed and
validated in a single sample of children and youth in
Tennessee Medicaid who recently initiated treatment
with a psychotropic medication. Although our case defi-
nition has face validity, it is unclear how well the case
definition may perform in more general populations
including those with existing diagnoses of diabetes mel-
litus and in adults. One might expect the PPV of our
DKA case definition to increase among those with
established diagnoses of diabetes mellitus, a necessary
precondition for DKA development. However, for many,
DKA may be the first manifestation of diabetes mellitus
because of delays in the diagnosis and/or treatment of
diabetes [17]. One might also suspect that our case defi-
nition may perform more poorly in adults because DKA
has classically been regarded as a feature of type 1
(rather than type 2) diabetes [18] and a more common
complication of diabetes mellitus in children and youth
than in adults [19]. However, more recent epidemiologi-
cal studies have documented increases in the occurrence
of DKA in adults and among patients with type 2 dia-
betes [20], although the majority of DKA cases occur in
the setting of type 1 diabetes [21]. Further investigations
of our DKA computer case definition in other settings
are needed.
Interpretation of our results should proceed with addi-
tional limitations in mind. First, our sample size was
small, and we were unable to abstract all records sought.
The precision of our PPV estimates was reduced as a
result. Second, we were unable to determine the sensi-
tivity of our DKA case definition because we did not
seek to identify cases presenting in the absence of an
inpatient diagnosis. We believe this is unlikely to occur
for moderate-to-severe DKA cases. However, some
patients with mild DKA may be discharged without sub-
sequent hospital admission after receiving appropriate
treatment in the emergency department [22]. Moreover,
determining sensitivity (the proportion of true DKA
cases that the case definition identifies as having DKA),
would quantify performance of the case definition only
for those already known to have DKA (established
cases). Our objective was to develop a DKA case defini-
tion for use in automated database studies, where
Bobo et al. BMC Medical Research Methodology 2011, 11:157
http://www.biomedcentral.com/1471-2288/11/157
Page 4 of 6suspected (not established) cases would be first identi-
fied. Our results suggest that a high proportion of these
will be true cases using our definition. Third, it should
be emphasized that our case definition, which relies on
inpatient ICD diagnosis codes from Tennessee Medicaid
medical claims data that may be encoded days or weeks
following discharge, is applicable to retrospective studies
that use automated databases as a data source. Other
data collection approaches should be considered for stu-
dies designed to identify cases prospectively. Finally,
while the rate of DKA misclassification was low, the
PPV was lower for antipsychotic initiators in our study
compared with control medication initiators. Our results
also suggest that the performance of our case definition
m a yv a r ys o m e w h a td e p e n d i n go nw h i c hc l i n i c a ls u b -
group is under investigation. Larger samples will be
needed to determine whether the performance of our
case definition varies according to drug exposure or
clinical subgroup of interest.
Conclusions
Diabetic ketoacidosis in children and youth can be iden-
tified in a computerized Medicaid database using our
case definition, which could be useful for automated
database studies in which drug-associated DKA is the
outcome of interest.
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